Synthesis and cytotoxic activity of a new potent daunomycinone derivative

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 24, 2002, Pages 3505-3507

  Aligiannis, Nectarios ^a   Pouli, Nicole ^a   Marakos, Panagiotis ^a   Skaltsounis, Alexios Leandros ^a   Pratsinis, Harris ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDO 3' BROMO 3' DEAMINO 4' DEOXYDAUNORUBICIN; DAUNOMYCINONE; DOXORUBICIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CARBOHYDRATE; DAUNORUBICIN; DRUG DERIVATIVE; NAPHTHACENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; LEUKEMIA L 1210; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; TRANSESTERIFICATION; ANIMAL; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG EFFECT; HYDROPHOBICITY; IC 50; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARBOHYDRATES; CELL DIVISION; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; MICE; NAPHTHACENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0036889643     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00823-5     Document Type: Article

References (22)

1. Arcamone F. Cancer Res. 45:1985;5995.
2. Gottesman M.M. Cancer Res. 53:1993;747.
3. Kaye S.B. Br. J. Cancer. 58:1988;691.
4. Monneret C., Eur J. Med. Chem. 36:2001;483.
5. Taatjes D.J., Fenick D.J., Gaudiano G., Koch T.H. Curr. Pharm. Des. 4:1998;203.
6. Arcamone F. In Anticancer Agents Based on Natural Product Models; Cassidy J. M., Douros, J. D. Eds.; Academic Press: New York, 1980; p 1.
7. Faccheti I., Grandi M., Cucchi P., Geroni C., Penco S., Vigevani A. Anticancer Drug Des. 5:1991;385.
8. Coley H.M., Twentyman P.R., Workman P. Anticancer Drug Des. 7:1992;471.
9. Demetzos C., Skaltsounis A.-L., Michel S., Tillequin F., Koch M., Anstett M., Leonce S., Piere A., Atassi Gh. Anticancer Drug Des. 9:1994;129.
10. Aligiannis N., Pouli N., Marakos P., Mitaku S., Skaltsounis A.-L., Leonce S., Piere A., Atassi Gh. Chem. Pharm. Bull. 48:2000;150.
11. Aligiannis N., Pouli N., Marakos P., Skaltsounis A.-L., Leonce S., Piere A., Atassi Gh. Bioorg. Med. Chem. Lett. 6:1996;2473.
12. Mitaku S., Skaltsounis A.-L., Tillequin F., Koch M. Synthesis. 1992;1068.
13. +).
14. +).
15. Evans M.E., Long R. Jr., Parrish F.W. J. Org. Chem. 33:1968;1074.
16. Lindhorst T.K., Thiem G. Carbohydr. Res. 209:1991;119.
17. +.
18. 3O-1), 33.8 (C-2), 20.2 (C-6).
19. 2Si), 17.8 (C-6).
20. +).
21. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Cancer Res. 48:1988;589.
22. Kostakis I.K., Magiatis P., Pouli N., Marakos P., Skaltsounis A.-L., Pratsinis H., Leonce S., Pierre A. J. Med. Chem. 45:2002;2599.